Inhibrx Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	1.8	2.19	7.23	12.89	13.21	8.6
Revenue Growth (YoY)	-17.88%	-69.69%	-43.89%	-2.44%	53.71%	-
Gross Profit	1.8	2.19	7.23	12.89	13.21	8.6
Selling, General & Admin	29.38	21.12	12.36	6.84	6.26	4.65
Research & Development	191.64	110.19	71.44	73.5	47.91	33.45
Other Operating Expenses	0	0	0	0	2.76	0
Operating Expenses	221.02	131.31	83.8	80.33	56.93	38.11
Operating Income	-219.22	-129.12	-76.56	-67.44	-43.71	-29.51
Interest Expense / Income	31.84	18.18	5.22	10.82	5.72	1.48
Other Expense / Income	-9.7	-2.08	-0.01	-2.14	1.07	0.07
Pretax Income	-241.36	-145.22	-81.77	-76.12	-50.5	-31.07
Income Tax	0	0	0	0	0.9	0.1
Net Income	-241.36	-145.23	-81.77	-76.12	-51.4	-31.16
Shares Outstanding (Basic)	47	40	38	25	18	18
Shares Outstanding (Diluted)	47	40	38	25	18	18
Shares Change	17.51%	5.52%	50.47%	39.15%	-	-
EPS (Basic)	-5.12	-3.62	-2.15	-3.01	-2.83	-1.72
EPS (Diluted)	-5.12	-3.62	-2.15	-3.01	-2.83	-1.72
Free Cash Flow	-197.9	-115.99	-81.13	-49.33	-33.89	-24.52
Free Cash Flow Per Share	-4.20	-2.89	-2.13	-1.95	-1.87	-1.35
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-12178.94%	-5890.37%	-1058.83%	-523.30%	-330.89%	-343.37%
Profit Margin	-13408.94%	-6625.27%	-1130.80%	-590.66%	-389.07%	-362.57%
Free Cash Flow Margin	-10994.56%	-5291.38%	-1122.00%	-382.77%	-256.52%	-285.29%
EBITDA	-206.56	-124.2	-73.86	-62.91	-42.27	-28.91
EBITDA Margin	-11475.67%	-5665.88%	-1021.46%	-488.14%	-319.92%	-336.37%
Depreciation & Amortization	2.96	2.85	2.69	2.39	2.52	0.68
EBIT	-209.52	-127.04	-76.55	-65.31	-44.78	-29.59
EBIT Margin	-11639.89%	-5795.71%	-1058.64%	-506.71%	-338.98%	-344.24%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).